Building a strong foundation of data to improve GHD treatment approaches
Versartis is committed to developing solutions to address the unmet needs of patients with GHD. By minimizing the treatment burden associated with current growth hormone injections, the goal is to transform the treatment paradigm for patients with GHD.
Versartis designed the somavaratan clinical trial program to:
- Build a deep and broad foundation of data focusing on patients with GHD
- Evaluate somavaratan as a twice-monthly treatment for GHD1,2
- Be representative of the patients that many endocrinologists see in clinical practice in the United States today by recruiting children with moderate GHD for the pediatric trials2,3